Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Current Liabilities (2020 - 2026)

Rani Therapeutics Holdings' Total Current Liabilities history spans 7 years, with the latest figure at $13.9 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities fell 31.17% to $13.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $13.9 million, a 31.17% decrease, with the full-year FY2025 number at $12.7 million, down 36.31% from a year prior.
  • Total Current Liabilities came in at $13.9 million for Q1 2026, up from $12.7 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $20.6 million in Q2 2025, with the low at $4.2 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $12.0 million across 5 years, with a median of $12.7 million in 2025.
  • Biggest five-year swings in Total Current Liabilities: plummeted 42.82% in 2022 and later soared 189.12% in 2024.
  • Year by year, Total Current Liabilities stood at $4.8 million in 2022, then skyrocketed by 65.92% to $8.0 million in 2023, then surged by 148.98% to $19.9 million in 2024, then tumbled by 36.31% to $12.7 million in 2025, then grew by 9.36% to $13.9 million in 2026.
  • Business Quant data shows Total Current Liabilities for RANI at $13.9 million in Q1 2026, $12.7 million in Q4 2025, and $19.1 million in Q3 2025.